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Purpose: To evaluate the association of the lysyl oxidase-like 1 (LOXL1) single nucleotide polymorphisms (SNPs) in the
Korean population with exfoliation syndrome (XFS) and to investigate the association between the SNPs and phenotypes
of XFS.
Methods: Eighty-nine unrelated patients with XFS and 146 unrelated control subjects were recruited. LOXL1 SNPs,
rs1048661, rs3825942, and rs2165241, were genotyped by direct DNA sequencing. Association between cases and
controls was analyzed and phenotypic features of XFS were compared in terms of the SNPs.
Results: The three SNPs were found to be significantly associated with XFS. After adjusting for rs3825942, rs2165241,
and other factors influencing the prevalence of XFS, only rs1048661 among three SNPs remained significant (95%
confidence interval=4.11–35.78, p=6.11×10−6). T allele and TT genotype of rs1048661 and C allele and CC genotype of
rs2165241 were associated with XFS, showing risk alleles and genotypes opposite to those reported in Caucasians. In the
haplotype analysis, T-G-C was the only risk haplotype (p=3.35×10−12), which was not associated with XFS in Caucasians.
No significant differences were noted in the allele and genotype frequencies depending on phenotypic features of XFS.
Conclusions: Three LOXL1 SNPs are associated with XFS in the Korean population. Risk alleles and genotypes of
rs1048661 and rs2165241 in Korean have a similar pattern with those of East Asians, including Japanese and Northern
Chinese, while they have a different pattern from those of Caucasians.
Exfoliation syndrome (XFS) is a complex, late-onset,
generalized disorder of the extracellular matrix characterized
by  production  and  progressive  accumulation  of  abnormal
fibrillar  aggregates  in  various  intraocular  and  extraocular
tissues [1,2]. Clinically, XFS is characterized by deposition
of  white  flake-like  material  on  all  tissues  of  the  anterior
segment of the eye [3]. In particular, gradual accumulations
of this material in the outflow pathways may cause a common
and  severe  type  of  chronic  open-angle  glaucoma.  XFS  is
acknowledged  as  the  most  common  identifiable  cause  of
open-angle glaucoma, accounting for about 25% of all open-
angle glaucoma worldwide [4]. The prevalence of XFS varies
widely among different ethnic populations. In people aged 60
years or older, XFS has been reported to be more common in
the Caucasian population with a prevalence of 10%–20% in
Northern Europeans [5-8], when compared with the Asian
population with a prevalence of 0.4% in Hong Kong Chinese,
0.7% in Singaporean, and 2.4% in Japanese [9-11].
Although the etiology and pathogenesis of XFS are still
unknown, recent molecular biologic and biochemical data
strongly  support  XFS  as  an  elastic  microfibrillopathy
associated  with  excessive  production  and  abnormal
aggregation  of  elastic  fiber  components,  enzymatic  cross-
linking  processes,  and  impaired  protection  mechanisms
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against  oxidative  and  cellular  stress  [12-15].  And  several
population-based and pedigree-based studies have shown that
genetic factors may play an important role in the pathogenesis
of XFS [16,17].
Recently,  a  genome-wide  association  study  in  the
Icelandic and Swedish population demonstrated a significant
association of one intronic single nucleotide polymorphisms
(SNP, rs2165241) and two exonic SNPs (rs1048661 [R141L]
and rs3825942 [G153D]), which are located in the first exon
of the lysyl oxidase-like 1 (LOXL1) gene on chromosomal
region 15q24.1, with XFS and exfoliation glaucoma (XFG)
[18]. LOXL1 is a member of the lysyl oxidase family of
enzymes, which catalyze covalent cross-linking of collagen
and  elastin  in  connective  tissues  through  oxidative
deamination [19]. A recent experimental study demonstrated
that differential regulation of ocular expression of LOXL1 is
dependent  on  the  phase  of  progression  of  the  fibrotic
exfoliation process, contributing to the pathogenesis of XFS
[20]. Thus, the hypothesis that defects in LOXL1 may cause
XFS is biologically reasonable.
Association between XFS and the three LOXL1 SNPs has
been  confirmed  in  many  Caucasian  populations  including
European, American, and Australian [21-25]. However, in the
Asian population, this association has been evaluated only in
Indian, Chinese, and Japanese [26-31]. Allelic and genotypic
distributions of the three SNPs were found to be drastically
different  among  different  ethnic  populations.  The  allelic
distribution of East Asian populations including Japanese and
Northern Chinese are reversed for rs1048661 and rs2165241
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The G allele of rs1048661 and the T allele of rs2165241,
identified  as  risk  alleles  in  Caucasians,  were  found  to  be
protective  in  East  Asians.  Of  particular  Interest,  genetic
diversity also occurs across different districts and populations
even in Asia. The Indian population showed risk alleles and
genotypes similar to those of Caucasians at rs1048661 and
rs2165241 [30]. In the Singaporean Chinese population, the
rs1048661, which is the predominant SNP associated with
XFS in East Asians, was not associated with the disease [31].
Therefore, this study was conducted to investigate the
association between the three LOXL1 SNPs and XFS in the
Korean  population.  In  addition,  we  investigated  the
association  between  the  three  SNPs  and  the  phenotypic
features of patients with XFS.
METHODS
Study subjects: Eighty-nine unrelated patients diagnosed with
XFS  including  XFG  and  146  unrelated  control  subjects
diagnosed  with  cataract,  primary  open  angle  glaucoma
(POAG),  chronic  angle  closure  glaucoma  (CACG),  or
secondary  glaucoma  were  recruited  from  the  Yeungnam
University Hospital in Daegu, Korea. This study adhered to
the tenets of the Declaration of Helsinki. The study protocol
was approved by the Institutional Review Board of Yeungnam
University Hospital, and informed consent was obtained from
all study participants.
All  subjects  underwent  comprehensive  ophthalmic
examinations  including  slit-lamp  biomicroscopy,
gonioscopy, and fundoscopy. Subjects with XFS were defined
as those with exfoliation material on the anterior lens capsule
and/or  pupillary  margin  in  mydriasis  by  slit  lamp
biomicroscopy. Secondary open-angle glaucoma due to XFS
was defined, if elevated intraocular pressure (>20 mmHg), an
open-angle  angle,  and  characteristic  glaucomatous  optic
neuropathy with compatible visual field loss were found with
clinical evidence of XFS. Control subjects included those with
cataract,  POAG,  CACG,  and  secondary  glaucoma  (e.g.,
uveitis-induced glaucoma, neovascular glaucoma) with no
clinical signs of XFS. To avoid possible misclassification of
latent XFS as controls, considering that XFS is a late-onset
disorder,  only  individuals  aged  60  years  or  older  were
recruited as controls.
Analysis  of  LOXL1  polymorphisms:  Genomic  DNA  was
extracted from whole blood and purified using the Qiagen
QIAamp  Blood  Kit  (Qiagen,  Valencia,  CA).  The  three
LOXL1 SNPs (rs1048661, rs3825942, and rs2165241) were
amplified  by  polymerase  chain  reaction  (PCR),  directly
sequenced, and genotyped. For PCR, two primer sets (for
rs1048661 and rs3825942 in exon 1: 5′-GGT GTA CAG CTT
GCT CAA CTC G-3′ and 5′-GTA GTA CAC GAA ACC CTG
GTC GTA-3′; for rs2165241 in intron 1: 5′-CTG CTC TGG
TCC TTA CCA GGT ACT-3′ and 5′-GTA GTG GCC AGA
GGT CTG CTA A-3′) were used under PCR conditions. The
PCR protocol was as follows: initial denaturation at 95 °C/15
min, followed by 35 cycles (94 °C/30 s, 62 °C 1 min 30 s,
72 °C/1 min 30 s), and a final extension at 72 °C/4 min.
Amplified PCR products were electrophoresed in 2% agarose
gel and stained with ethidium bromide and purified by the
QIAquick PCR purification kit (Qiagen). Genotypes of the
three  LOXL1  SNPs  were  determined  by  direct  DNA
sequencing, using the BigDye Terminator v3.1 Kit (Applied
Biosystems,  Foster  City,  CA)  in  an  ABI  PRISMTM  3100
Genetic Analyzer (Applied Biosystems, Perkin-Elmer).
Statistical  analysis:  Hardy–Weinberg  equilibrium  of  the
genotypic frequencies among cases and separately among
controls was tested using the χ2 test in SAS Genetics (ver. 9.2;
SAS  Institute  Inc.,  Cary,  NC).  Allele  and  genotype
frequencies between cases and controls were compared by the
χ2 test and odds ratio (OR) with 95% confidence interval (CI)
to XFS was calculated by the logistic regression method.
Allele and genotype frequencies between subgroups, i.e., XFS
without glaucoma and XFG in cases, and cataract, POAG,
CACG,  and  secondary  glaucoma  in  controls  were  also
compared  using  the  methods  mentioned  above.  Pairwise
linkage  disequilibrium  (LD)  analysis  among  the  three
LOXL1 SNPs was performed, and individual haplotype and
their estimated population frequencies were inferred using
HAPLOVIEW  (ver.  4.2;  Daly  Lab,  Broad  Institute,
Cambridge, MA). Logistic regression analysis was used for
evaluation  of  the  effects  of  multiple  covariates  when
comparing XFS cases and controls. The covariates were the
risk  genotypes  of  the  three  LOXL1  SNPs,  sex,  diabetes,
hypertension, retinal vein occlusion, cardiovascular disease,
and cerebrovascular disease. As a diagnostic test for XFS,
sensitivity (SE), specificity (SP), and positive and negative
predictive  values  (PPV  and  NPV)  of  the  risk  alleles  and
genotypes for the three SNPs were calculated for assessment
of their clinical values.
RESULTS
The mean age of 89 Korean patients, including 28 cases with
XFS without glaucoma and 61 cases with XFG, was 71.7±7.7
years (age range 53 to 92) and for 146 Korean control subjects
including cataract, POAG, CACG, and secondary glaucoma,
the mean age was 72.9±6.4 years (age range 60 to 90). The
gender distribution was 48 (53.9%) males and 41 (46.1%)
females  in  cases,  and  67  (45.9%)  males  and  79  (54.1%)
females in controls. There were no significant differences in
age  and  gender  distribution  between  cases  and  controls
(p=0.216,  p=0.232,  respectively).  Demographic
characteristics of the study subjects are shown in Table 1.
Distributions of allele and genotype frequencies for SNPs
rs1048661, rs3825942, and rs2165241 are shown in Table 2.
The genotype frequencies of the three LOXL1 SNPs in control
subjects were in Hardy–Weinberg equilibrium (HWE). The
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in HWE. On the other hand, the genotype distributions of the
SNPs rs1048661 and rs2165241 showed a slight deviation
from  the  HWE.  We  confirmed  the  reproducibility  of
genotyping of rs1048661 and rs2165241 by repeating DNA
sequencing. Previous studies have shown that deviation from
HWE in affected individuals may be indicative of the presence
of susceptibility loci.
While no significant differences in allele and genotype
frequencies were found between the XFS subgroup and the
XFG subgroup in cases, and among subgroups, including
cataract, POAG, CACG, and secondary glaucoma in controls,
significant differences in allele and genotype frequencies of
the three LOXL1 SNPs were observed between entire cases
and control subjects. SNP rs1048661 was associated with XFS
including  XFG  (p=5.744×10−12),  with  the  at-risk  T  allele
presenting  in  93%  of  patients  (OR=7.02,  95%  CI=3.80–
12.97), while the T allele was detected in 64% of control
subjects. The genotype of rs1048661 was also associated with
XFS  including  XFG  (p=2.066×10−12),  with  genotype  TT
found in 90% of patients (OR=11.39, 95% CI=5.31–24.42),
while the TT was detected in only 44% of control subjects. At
rs3825942, the frequencies of the G allele and GG genotype
at  rs3825942  were  significantly  higher  in  cases  than  in
controls  (p=0.0003,  OR=6.93,  95%  CI=2.09–23.01;
p=0.0003, OR=7.11, 95% CI=2.10–24.08, respectively). The
allele  C  and  the  genotype  CC  of  rs2165241  presented  at
significantly  higher  frequencies  in  cases  than  in  controls
(p=0.0011,  OR=5.94,  95%  CI=1.35–11.71;  p=0.0008,
OR=8.58, 95% CI=1.97–37.16, respectively).
Considering  that  XFS  is  a  late-onset  disorder,  we
compared the results of association analysis with controls
including only patients aged 70 years or older to those of entire
controls  (Table  2).  The  T  allele  and  TT  genotype  of
rs1048661 and the G allele and GG genotype of rs3825942
presented at lower frequencies in controls including patients
aged 70 years or older than entire controls, conferring an
increased risk to XFS, while the C allele and CC genotype of
rs2165241  showed  similar  frequencies  between  the  two
subgroups.
In  addition,  we  compared  the  frequencies  of  LOXL1
polymorphisms by dividing the phenotypes of XFS into either
XFS without glaucoma or XFG and into either unilateral or
bilateral involvement (Table 3 and Table 4). Patients with
XFG did not show an increasing tendency of risk allele and
genotype frequencies of the three SNPs, compared to those
with  XFS  without  glaucoma.  And  patients  with  bilateral
involvement did not have an increasing tendency of risk allele
and genotype frequencies of three SNPs, compared to those
with unilateral involvement.
Pairwise linkage disequilibrium (LD) analysis showed
that  exonic  SNPs,  rs1048661  and  rs3825942,  were  in
complete  LD  (Coefficient  of  LD  [D’]=1.00).  SNP
rs1048661 and intronic rs2165241 were also in strong LD
(D’=0.87) while rs3825942 and rs2165241 were not in LD
(D’=0.00). Haplotypes defined by consideration of LD of the
three  SNPs  were  estimated  (Table  5).  Seven  of  the  eight
theoretically  possible  haplotypes  were  detected  in  the
haplotype analysis. The T-G-C haplotype was identified as
having  a  significant  association  with  XFS,  conferring  an
approximately  sevenfold  increased  risk  to  the  disease
(OR=6.61, 95% CI=3.58–12.22, p=3.352×10−12). The G-G-T
haplotype, identified as a risk haplotype in Caucasians, was
found to be protective in our study (OR=0.24, 95% CI=0.09–
0.64,  p=0.002).  In  addition,  the  haplotype  G-G-C  was
observed  only  in  cases,  while  the  haplotype  G-A-T  was
exclusively observed in controls.
TABLE 1. DEMOGRAPHIC CHARACTERISTICS OF THE STUDY SUBJECTS.
  Cases Controls p value
Number of subjects 89   146    
Subgroups (number) XFS 28 Cataract 90  
  XFG 61 POAG 32  
      CACG 19  
      Secondary glaucoma 5  
Gender (%)
Male 48 (53.9%)   67 (45.9%)   0.232
Female 41 (46.1%)   79 (54.1%)    
Age
Mean±SD 71.7±7.7   72.9±6.4   0.216
Range 53-92   60-90    
         XFS, Exfoliation syndrome; XFG, Exfoliation glaucoma; POAG, Primary open angle glaucoma; CACG, Chronic angle closure
         glaucoma; SD, Standard deviation.
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2813Step-wise logistic regression was used for simultaneous
analysis of the effect of multiple covariates when comparing
XFS/XFG  patients  with  control  subjects  (Table  6).  After
adjusting for the effect of the risk genotypes of the three
LOXL1 SNPs and factors known to influence the prevalence
of XFS, including sex, diabetes mellitus, hypertension, retinal
vein occlusion, cardiovascular disease, and cerebrovascular
disease,  only  rs1048661  among  three  SNPs  remained
significantly associated with disease risk (OR=12.13, 95%
CI=4.11–35.78, p=6.113×10−6). Ischemic heart disease also
showed a marginal association with disease risk (OR=7.75,
95% CI=1.41–42.51, p=0.018).
The risk alleles and genotypes of the three SNPs were
analyzed for their ability to predict the affection status (Table
7). Although the SE was high, SP, PPV, and NPV were low
for the risk alleles and genotypes of all three SNPs.
DISCUSSION
Since Thorleifsson et al. [18] reported results of a genome-
wide association study of XFS, which identified three strongly
TABLE 5. HAPLOTYPE ASSOCIATION ANALYSIS BETWEEN LOXL1 SNPS AND XFS/XFG.
Haplotype Proportion
rs1048661 rs3825942 rs2165241 Case Control p value* OR* (95% CI) Adjusted OR** (95% CI)
T G C 0.93 0.66 3.352×10−12 6.61 (3.58–12.22) 7.87 (4.10–15.11)
T G T 0.01 0.00 0.723 1.64 (0.10- 26.45) 1.46 (0.09- 23.67)
T A C 0.02 0.10 0.002 0.21 (0.07- 0.60) 0.20 (0.07–0.59)
T A T 0.01 0.07 0.002 0.08 (0.01- 0.61) 0.06 (0.01–0.49)
G G C 0.01 0.05 0.033 0.23 (0.05–1.01) 0.19 (0.04–0.86)
G G T 0.03 0.11 0.002 0.24 (0.09–0.64) 0.22 (0.08–0.60)
G A T 0 0.02 0.054 NA NA
         LOXL1, Lysyl oxidase-like 1; SNP, single nucleotide polymorphism; XFS, Exfoliation syndrome; XFG, Exfoliation glaucoma;
         OR, odds ratio; NA; non applicable. The single asterisk indicates the p values and OR ratios derived from comparison of the
         specific haplotype with all of the other haplotypes. The double asterisk indicates the OR values derived from comparison of
         each haplotype with other haplotypes, age, sex, RVO, DM, HTN, cardiovascular and cerebrovascular disease.
TABLE 6. ESTIMATES OF XFS/XFG RISK FROM A LOGISTIC REGRESSION MODEL (MULTIVARIATE ANALYSIS).
Regression term OR 95% CI p value
rs1048661 TT versus TG+GG 12.13 4.11–35.78 6.113×10−6
rs3825942 GG versus GA+AA 1.13 0.23–5.50 0.878
rs2165241 CC versus CT+TT 2.93 0.52–16.38 0.222
Age/year 0.99 0.95–1.04 0.715
Sex (male versus female) 0.88 0.46–1.66 0.685
DM versus no DM 0.33 0.14–0.76 0.009
HTN versus no HTN 1.19 0.59–2.42 0.623
RVO versus no RVO 0.20 0.02–1.82 0.153
CVA+TIA versus no CVA+TIA 1.38 0.37–5.11 0.628
IHD versus no IHD 7.75 1.41–42.51 0.018
         XFS, Exfoliation syndrome; XFG, Exfoliation glaucoma; OR, odds ratio; DM, Diabetes mellitus; HTN, Hypertension; RVO,
         Retinal vein occlusion; CVA, Cerebrovascular accident; TIA, Transient ischemic attack; IHD, Ischemic heart disease.
TABLE 7. SENSITIVITY, SPECIFICITY, AND POSITIVE AND NEGATIVE PREDICTIVE VALUES FOR THE THREE LOXL1 SNPS.
SNP SE (95% CI) SP (95% CI) PPV (95% CI) NPV (95% CI)
rs1048661
Allele (T) 0.927 (0.889–0.965) 0.356 (0.285–0.427) 0.467 (0.393–0.541) 0.889 (0.843–0.935)
Genotype (TT) 0.889 (0.836–0.962) 0.562 (0.458–0.666) 0.556 (0.452–0.660) 0.901 (0.839–0.963)
rs3825942
Allele (G) 0.983 (0.964–1.002) 0.106 (0.061–0.151) 0.401 (0.329–0.473) 0.912 (0.870–0.954)
Genotype (GG) 0.966 (0.928–1.004) 0.199 (0.116–0.282) 0.424 (0.321–0.527) 0.906 (0.845–0.967)
rs2165241
Allele (C) 0.983 (0.964–1.000) 0.093 (0.050–0.136) 0.398 (0.326–0.470) 0.900 (0.000–0.944)
Genotype (CC) 0.978 (0.947–1.000) 0.164 (0.087–0.241) 0.416 (0.313–0.519) 0.923 (0.867–0.977)
        SNP, single nucleotide polymorphism; SE, sensitivity; SP, specificity; PPV, positive predictive values; NPV, negative predictive
        values.
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2814associated polymorphisms of LOXL1, the association between
XFS and the LOXL1 gene has been confirmed in various
Caucasian populations, including European, American, and
Australian [21-25]. However, this association in the Asian
population has been reported only in Indian, Chinese, and
Japanese  [26-31].  Thus,  we  investigated  the  association
between LOXL1 and XFS in the Korean population. In the
current study, all three LOXL1 SNPs, rs1048661, rs3825942,
and rs2165241, were found to have a significant association
with XFS.
Allelic and genotypic distributions of the three LOXL1
SNPs were quite different between Caucasians and Asians.
The risk for disease in Caucasians was associated mostly
strongly with G allele and GG genotype of rs1048661, G allele
and GG genotype of rs3825942, and T allele and TT genotype
of rs2165241 [21-25]. However, Asians have shown different
association results among different populations and districts.
While  the  Indian  study  showed  that  the  risk  alleles  and
genotypes of rs1048661 and rs3825942 were consistent with
those reported in Caucasians [30], studies from Japanese and
Northern Chinese populations revealed that T allele and TT
genotype of rs1048661 and C allele and CC genotype of
rs2165241 were associated with XFS, providing reversed risk
alleles and genotypes from Caucasians [26-29]. Moreover, in
the Southern Chinese population, no association with XFS
was found for rs1048661, which is the predominant SNP
associated with XFS in Northern Chinese population [31]. Our
study showed that T allele and TT genotype of rs1048661, G
allele and GG genotype of rs3825942, and C allele and CC
genotype  of  rs2165241  were  significantly  associated  with
Korean XFS patients. We found that the allelic and genotypic
distributions of rs1048661 and rs2165241 in Korean have a
similar pattern with those of East Asians, including Japanese
and Northern Chinese, while they have a different pattern
from those of Caucasians. However, the allelic and genotypic
distribution of rs3825942 followed a similar pattern in all
populations, including Caucasians and Asians. Exceptionally,
a study in a black South African population reported that the
risk at rs3825942 was the A allele not the G allele observed
to increase risk in all other reported population [32]. The
reasons  for  the  discrepancy  in  the  allelic  and  genotypic
distributions of these LOXL1 SNPs among XFS patients with
different ethnicities remain unknown.
Considering that XFS is a late-onset disease, this study
essentially included patients aged 60 years or older as control
subjects. And, to reduce the chance of misclassifying latent or
preclinical XFS into controls, only patients aged 70 years or
older  were  re-grouped  as  control  subjects.  Comparison
between XFS/XFG patients and control subjects aged 70 years
or older revealed a more significant increase in the association
of the LOXL1 SNPs with XFS except for rs2165241 showing
similar significance.
In the present study, the allelic and genotypic frequencies
of the three LOXL1 SNPs in the two XFS sub-phenotypes, i.e,
XFS without glaucoma and XFG, were similar and showed
no statistical significance. This finding is consistent with those
of previous studies [18,27]. However, Schlötzer-Schrehardt
et al. [20] reported decreased LOXL1 expression in cadaveric
ciliary  body  specimens  from  XFG.  Khan  et  al.  [33]  also
demonstrated that LOXL1 gene expression was reduced in
lens capsule specimens from XFG but not XFS individuals
and suggested a causative functional relationship between
LOXL1 expression and XFG. In addition, we compared the
allelic and genotypic frequencies of the three LOXL1 SNPs
between the XFS sub-phenotypes divided into unilateral or
bilateral involvement, which has not been evaluated so far.
We found no significant difference in the comparison. Thus,
it is difficult to explain these phenotype differences on the
basis of the alleles and genotypes of LOXL1. These results
suggest that LOXL1 is more likely a contributing factor to
disease  onset  of  XFS,  rather  than  a  modifying  factor  for
progression  into  several  different  phenotypes,  and  other
genetic  or  environmental  factors  may  be  associated  with
phenotype differences in patients with XFS.
Using haplotype-based association analysis, the T-G-C
haplotype, which was not associated with XFS in Caucasian
populations,  was  the  only  risk  haplotype  in  the  Korean
population, as it was in the East Asian populations including
the Japanese and Northern Chinese [26,27,29]. Moreover, the
G-G-T  haplotype,  which  was  the  dominant  haplotype  in
Caucasian populations [21,22,24], was a protective haplotype
in our study. The frequency of the T-G-C haplotype as the
major haplotype in the Korean population was 93%, which is
consistent  with  88%–94%  reported  in  the  East  Asian
population  including  the  Japanese  and  Northern  Chinese
[26,27,29],  whereas  in  Singaporean  Chinese,  the  T-G
haplotype  defined  by  rs1048661  and  rs3825942  was  not
associated with XFS [31]. This discrepancy observed in the
risk  haplotypes  between  East  Asians  and  Singaporean
Chinese may in part be caused by the effects of other unlinked
modifier  genes  and/or  environmental  factors  influencing
disease penetrance in these two different populations.
After adjusting for the effect of risk genotypes of the three
LOXL1 SNPs and factors known to influence the prevalence
of XFS, including sex, diabetes mellitus, hypertension, retinal
vein occlusion, cardiovascular disease, and cerebrovascular
disease,  only  rs1048661  among  the  three  LOXL1  SNPs
showed an independent association with XFS in the Korean
population,  suggesting  that  the  other  two  SNPs  are  not
independent, but are more likely to be genetic markers in LD
with rs1048661. Chen et al. [29] reported similar results that
the  association  between  the  two  SNPs,  rs3825942  and
rs2165241,  and  XFS  was  no  longer  significant  after
controlling for rs1048661 in the Northern Chinese population.
Ozaki  et  al.  [27]  also  showed  that  rs3825942  was  not
independent,  but  highly  correlated  with  rs1048661  in  the
Japanese population. On the other hand, in an American study,
rs1048661 was not associated with XFS after controlling for
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2815the other two SNPs [34]. So far, however, there has been no
consolidated evidence to show which SNPs plays a prominent
major role in the molecular pathogenesis of XFS. A recent
study  for  investigation  of  genotype-correlated  ocular
expression of LOXL1 showed that LOXL1 expression was
significantly increased in early XFS stages irrespective of the
individual genotype [20]. These findings imply that other yet
unidentified genetic and/or environmental factors unlinked to
the LOXL1 gene may be necessary to trigger the development
of XFS.
Risk alleles and genotypes of the three LOXL1 SNPs
appeared to have high sensitivity; However, specificity and
predictive values appeared low. Therefore, at present, genetic
screening tests for these alleles and genotypes may be of
limited usefulness.
In conclusion, we confirmed significant associations of
the three LOXL1 SNPs with XFS in the Korean population.
While allelic, genotypic, and haplotypic frequencies differed
between Korean XFS patients and Caucasian XFS patients,
consistencies were observed in the allelic, genotypic, and
haplotypic frequencies of the three SNPs among East Asian
populations,  including  Korean,  Japanese,  and  Northern
Chinese. These LOXL1 polymorphisms showed no significant
correlation with the phenotypic features of XFS patients. The
role of these SNPs in pathogenesis of XFS will require further
study, and additional studies are also needed to unravel other
genetic  and/or  environmental  factors  contributing  to  the
different prevalence rates among ethnical populations and
modulating the phenotypic expression of XFS.
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